Literature DB >> 1547916

The effects of different plasma insulin concentrations on lipolytic and ketogenic responses to epinephrine in normal and type 1 (insulin-dependent) diabetic humans.

A Avogaro1, A Valerio, L Gnudi, A Maran, M Miola, E Duner, C Marescotti, E Iori, A Tiengo, R Nosadini.   

Abstract

This study was performed to verify: (1) the ability of different insulin concentrations to restrict the lipolytic and ketogenic responses to exogenous epinephrine administration; (2) whether the ability of insulin to suppress the lipolytic and ketogenic responses during epinephrine administration is impaired in Type 1 (insulin-dependent) diabetic patients. Each subject was infused on separate occasions with insulin at rates of 0.2, 0.4, and 0.8 mU.kg-1.min-1 while normoglycaemic. To avoid indirect adrenergic effects on endocrine pancreas secretions, the so-called "islet clamp" technique was used. Rates of appearance of palmitic acid, acetoacetate, and 3-hydroxybutyrate were simultaneously measured with an infusion of 13C-labelled homologous tracers. After a baseline observation period epinephrine was exogenously administered at a rate of 16 ng.kg-1.min-1. At low insulin levels (20 microU/ml) the lipolytic response of comparable magnitude was detected in normal and Type 1 diabetic patients. However, the ketogenic response was significantly higher in Type 1 diabetic patients. During epinephrine administration, similar plasma glucose increments were observed in the two groups (from 4.74 +/- 0.53 to 7.16 +/- 0.77 mmol/l (p less than 0.05) in Type 1 diabetic patients and from 4.94 +/- 0.20 to 7.11 +/- 0.38 mmol/l (p less than 0.05) in normal subjects, respectively). At intermediate insulin levels (35 microU/ml) no significant differences were found between Type 1 diabetic patients and normal subjects, whereas plasma glucose levels rose from 4.98 +/- 0.30 to 6.27 +/- 0.66 mmol/l (p less than 0.05) in Type 1 diabetic patients, and from 5.05 +/- 0.13 to 6.61 +/- 0.22 mmol/l (p less than 0.05) in normal subjects. At high insulin levels (70 microU/ml) the lipolytic response was detectable only in Type 1 diabetic patients; the ketogenic response was reduced in both groups. During the third clamp, a significant rise in plasma glucose concentration during epinephrine infusion was observed in both groups. In conclusion this study shows that at low insulin levels Type 1 diabetic patients show an increased ketogenic response to epinephrine, despite their normal nonesterified fatty acid response. Instead, high insulin levels are able to restrict the ketogenic response to epinephrine in both normal and Type 1 diabetic subjects, although there is a still detectable lipolytic response in the latter. In the presence of plasma free insulin levels that completely restrict the ketogenic response in the same group, there is still a distinct glycaemic response. Plasma insulin levels in Type 1 diabetic patients are a major determinant of the metabolic response to epinephrine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1547916     DOI: 10.1007/bf00402544

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

Review 1.  Ketone body metabolism: a physiological and clinical overview.

Authors:  R Nosadini; A Avogaro; A Doria; P Fioretto; R Trevisan; A Morocutti
Journal:  Diabetes Metab Rev       Date:  1989-05

2.  Models to interpret kinetic data in stable isotope tracer studies.

Authors:  C Cobelli; G Toffolo; D M Bier; R Nosadini
Journal:  Am J Physiol       Date:  1987-11

3.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

4.  Enhanced glycemic responsiveness to epinephrine in insulin-dependent diabetes mellitus is the result of the inability to secrete insulin. Augmented insulin secretion normally limits the glycemic, but not the lipolytic or ketogenic, response to epinephrine in humans.

Authors:  M A Berk; W E Clutter; D Skor; S D Shah; R P Gingerich; C A Parvin; P E Cryer
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

5.  Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes.

Authors:  M Press; W V Tamborlane; R S Sherwin
Journal:  N Engl J Med       Date:  1984-03-29       Impact factor: 91.245

6.  Effect of epinephrine and somatostatin-induced insulin deficiency on ketone body kinetics and lipolysis in man.

Authors:  M Weiss; U Keller; W Stauffacher
Journal:  Diabetes       Date:  1984-08       Impact factor: 9.461

7.  Lipid transport in the human newborn. Palmitate and glycerol turnover and the contribution of glycerol to neonatal hepatic glucose output.

Authors:  P F Bougnères; I E Karl; L S Hillman; D M Bier
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

8.  Effect of epinephrine on the relationship between nonesterified fatty acid availability and ketone body production in postabsorptive man: evidence for a hepatic antiketogenic effect of epinephrine.

Authors:  M Beylot; B Beaufrere; J P Riou; Y Khalfallah; A Moneger; M Odeon; R Cohen; R Mornex
Journal:  J Clin Endocrinol Metab       Date:  1987-11       Impact factor: 5.958

9.  Inhibitory effect and mode of action of somatostatin on lipolysis in chicken adipocytes.

Authors:  M T Strosser; D Di Scala-Guenot; B Koch; P Mialhe
Journal:  Biochim Biophys Acta       Date:  1983-09-22

10.  Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man.

Authors:  W E Clutter; D M Bier; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

View more
  3 in total

Review 1.  Diabetes mellitus and burns. Part I-basic science and implications for management.

Authors:  Ioannis Goutos; Rebecca Spenser Nicholas; Atisha A Pandya; Sudip J Ghosh
Journal:  Int J Burns Trauma       Date:  2015-03-20

2.  Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes.

Authors:  Mads V Svart; Nikolaj Rittig; Ulla Kampmann; Thomas S Voss; Niels Møller; Niels Jessen
Journal:  Diabetologia       Date:  2017-04-07       Impact factor: 10.122

3.  Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis.

Authors:  Natalia M Branis; Steven D Wittlin
Journal:  Case Rep Endocrinol       Date:  2015-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.